Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?

PURPOSE OF REVIEW To summarize the recent studies directly comparing LDL and lipoprotein(a) as causal factors for cardiovascular disease and mortality. RECENT FINDINGS In approximately 100,000 individuals from the Copenhagen General Population Study for risk of myocardial infarction, in observational analyses per 39 mg/dl (1 mmol/l) cholesterol increase, the hazard ratio was 1.3 (95% confidence interval: 1.2-1.3) for LDL cholesterol and 1.6 (1.4-1.9) for lipoprotein(a) cholesterol. In corresponding genetic analyses, the causal risk ratio was 2.1 (1.3-3.4) for LDL and 2.0 (1.6-2.6) for lipoprotein(a). Also, a 15 mg/dl (0.39 mmol/l) cholesterol increase was associated with a hazard ratio for cardiovascular mortality of 1.05 (1.04-1.07) for LDL cholesterol and 1.18 (1.12-1.25) for lipoprotein(a) cholesterol. Corresponding values for all-cause mortality were 1.01 (1.00-1.01) for LDL cholesterol and 1.07 (1.04-1.10) for lipoprotein(a) cholesterol. In genetic, causal analyses, the mortality increases for elevated lipoprotein(a) appeared to be through apolipoprotein(a) kringle IV-2 rather than through lipoprotein(a) levels per se. SUMMARY On cholesterol scales, lipoprotein(a) and LDL appeared equal as causal factors for myocardial infarction; however, lipoprotein(a) was most important for mortality. Lipoprotein(a) effects may not only be due to cholesterol content but could also be due to the structure of lipoprotein(a) resembling plasminogen.

[1]  J. Tardif,et al.  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.

[2]  J. Witztum,et al.  Statin therapy increases lipoprotein(a) levels. , 2020, European heart journal.

[3]  J. Leipsic,et al.  From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[4]  B. Nordestgaard,et al.  High lipoprotein(a) and high risk of mortality. , 2019, European heart journal.

[5]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[6]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) and Risk of Ischemic Stroke. , 2019, Journal of the American College of Cardiology.

[7]  W. Shen,et al.  Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion , 2019, Cardiovascular Diabetology.

[8]  B. Nordestgaard,et al.  Antisense Oligonucleotides Targeting Lipoprotein(a) , 2019, Current Atherosclerosis Reports.

[9]  M. Koschinsky,et al.  Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. , 2022, Journal of clinical lipidology.

[10]  R. Klingel,et al.  Lipoprotein(a) and mortality—a high risk relationship , 2019, Clinical Research in Cardiology Supplements.

[11]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[12]  K. Parhofer,et al.  Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). , 2019, Pathology.

[13]  Chao He,et al.  Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention , 2018, Archives of medical science : AMS.

[14]  A. Sahebkar,et al.  Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials , 2018, Scientific Reports.

[15]  J. Ralphe,et al.  In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. , 2018, Journal of clinical lipidology.

[16]  F. Kronenberg,et al.  Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials , 2018, The Lancet.

[17]  L. Tokgozoglu,et al.  Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. , 2018, Journal of the American College of Cardiology.

[18]  G. Hillis,et al.  Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. , 2018, Journal of clinical lipidology.

[19]  Cheng-gang Zhu,et al.  Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study , 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[20]  B. Nordestgaard,et al.  Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy , 2018, Nature Reviews Cardiology.

[21]  Jennifer G. Robinson,et al.  Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.

[22]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[23]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[24]  Jennifer G. Robinson,et al.  Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[25]  D. Rader,et al.  Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial , 2015, The Lancet.

[26]  Improve-It Investigators Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[27]  B. Nordestgaard,et al.  Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.

[28]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[29]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[30]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[31]  A. Khera,et al.  Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[32]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[33]  W. Lehmacher,et al.  Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study , 2013, Circulation.

[34]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[35]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[36]  G. Hansson,et al.  The immune system in atherosclerosis , 2011, Nature Immunology.

[37]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[38]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[39]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[40]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[41]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[42]  Eric Boerwinkle,et al.  Sequence Variations in PCSK 9 , Low LDL , and Protection against Coronary Heart Disease , 2006 .

[43]  J. Witztum,et al.  Oxidized low density lipoprotein and innate immune receptors , 2003, Current opinion in lipidology.

[44]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[45]  K. V. van Dijk,et al.  Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[46]  R A Kronmal,et al.  Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. , 1998, JAMA.

[47]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[48]  J. Goldstein,et al.  Teaching old dogmas new tricks , 1987, Nature.

[49]  M. Brown,et al.  Plasma lipoproteins: teaching old dogmas new tricks. , 1987, Nature.

[50]  S. Srinivasan,et al.  Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. , 1986, Atherosclerosis.

[51]  M. Kuroda,et al.  Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.

[52]  M. Brown,et al.  Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. , 1974, The Journal of biological chemistry.